Prostate cancer is the second commonest cause of cancerrelated mortality among men in England and Wales, with nearly 9000 deaths recorded in 1994. It has a long natural history characterized by insidious progression over a period that may exceed 15 years. Death is invariably due to metastatic disease and, with over 3000 individuals succumbing each year under the age of 75, life expectancy may be substantially reduced, particularly among men approaching retirement. With a growing population at risk of developing prostate cancer and an increasing age-specific incidence, the gradual rise in mortality observed throughout this century will continue. Strategies to reduce the morbidity and mortality of metastatic disease depend on curative treatment of early tumours destined to become life-threatening, or their prevention.
Cancer diagnosed after the onset of symptoms is all too frequently incurable, despite current clinical trends to establish the diagnosis at an early tumour stage in those patients with long life expectancy. Radical local treatment seems to achieve long-term disease-free survival in the majority of men with organ-confined disease but its efficacy is yet to be proven in a randomized study and other issues such as morbidity and cost remain unresolved. Accordingly, screeningl'2 and treatment of early prostate cancer3 '4 are currently under evaluation in Europe and the United States.
Clinicopathological concern about early detection of prostate cancer has stimulated a greater awareness of morphological abnormalities that may represent precursor lesions-most notably, prostatic intra-epithelial neoplasia (PIN). Characterization ofPIN has enhanced current concepts of prostatic carcinogenesis and tumour behaviours56. PUTATIVE 
PRECURSOR LESIONS
The clinical importance of a particular histological lesion depends on the reliability of its diagnosis and the implications for further management of the patient. The former requires diagnostic criteria that are generally acceptable and reproducible for the histologist, while the latter relates to clinical behaviour and additional information that the diagnosis provides within the clinical context. ' Atypical adenomatous hyperplasia (AAH) AAH is a primarily architectural abnormality of gland structure comprising a localized proliferation of small acini. It may be found throughout the prostate, but most commonly in the transition zone. Cytological changes are minimal and no strong micro-anatomical or chromosomal relationship has been demonstrated between AAH and invasive cancer. Its importance relates to morphological distinction from well-differentiated carcinoma. Widely different prevalence rates are reported, probably reflecting variation in diagnostic interpretation. While there is as yet no other lesion that could represent a precursor for well differentiated transition zone tumours, evidence to support premalignant status is lacking7 and follow-up studies have not demonstrated any increased risk of cancer8.
Prostatic intra-epithelial neoplasia PIN is characterized by cytological abnormalities within the pre-existing duct-acinar system. Like cancer, it is more common in the peripheral zone9-12. Two grades are described-namely, low-grade and high-grade-based on the degree of cytological changes, a distinction that also seems to reflect its clinical importance. The cytological features resemble those of carcinoma but are largely confined to the luminal cell layer. There is increasing cell crowding, number and size of nucleoli, anisonucleosis, and hyperchromasia with minimal basal cell layer disruption1 3 Four distinct architectural patterns are recognized-tufting, micropapillary, cribriform and flat-which may merge with one another14.
The grading of PIN is by consensus criteria, and consistency in the diagnosis of high-grade PIN between histopathologists has been achieved15. Therefore a reliable diagnosis should be possible in routine clinical practice. Recognition of low-grade PIN is less certain16; and, since it does not provide any clear clinical message, many histopathologists do not report it.
High-grade PIN fulfils the major criteria for a precursor for prostatic adenocarcinoma, particularly for tumours that de novo are less than well differentiated10: it qualifies in terms of morphological similarity, spatial association, and biomarker abnormalities intermediate between benign epithelium and cancer, supported by epidemiological and clinical evidence. Although the cytological abnormalities associated with PIN manifest as a continuum between benign tissue and invasive cancer, this is rarely represented in histological specimens and an abrupt change is characteristically observed where high-grade PIN meets benign epithelium. Any relation other than morphological between low-grade PIN and either high-grade PIN or cancer is unclear at present. High-grade PIN is commonly present adjacent to smaller invasive tumours and there seems to be an inverse relation between the volume of PIN and carcinoma that would be consistent with the cancer overgrowing the precursor lesion17. Both are commonly multifocal and therefore PIN may also be present elsewhere within a prostate harbouring carcinoma.
Expert diagnostic systems are currently being evaluated that use computerized image analysis to recognize the specific architectural and cytological criteria associated with PIN18. Diagnosis is defined by numerical characterization of the degree and range of these changes and construction of Bayesian belief networks. Such systems may have an important role in providing a standard of reproducibility and also a means for auditing diagnostic practice.
Malignancy associated changes (MAC)
MAC represent precancerous changes in the epithelium that are not associated with morphological abnormalities and therefore cannot be diagnosed with a microscope. Although demonstrated with malignancy in surface epithelia such as cervix and colon, their existence and importance in the prostate is unknown.
INCIDENCE AND EPIDEMIOLOGY OF PIN
The prevalence of PIN increases with age, parallel with that of cancer and predating it by at least 5 years9'1920.
Histological examination of specimens obtained at cystoprostatectomy for transitional cell carcinoma21 and at necropsy13 has consistently shown that PIN is more frequently present in men who have prostate cancer than in those who do not-59-100% versus 46-72%, respectively9'21. It is also more extensive and of higher grade in men with cancer, particularly those with multifocal cancer.
High-grade PIN can be documented from the third decade and its extent increases with age20. It is more prevalent and extensive among black Americans than white Americans, and multifocal PIN in particular appears at a younger age in black Americans, consistent with their increased risk of cancer. A similar discrepancy has been reported between African-Brazilian and white Brazilian men22.
CLINICAL IMPLICATIONS OF PIN
The clinical importance of solitary high-grade PIN in needle core specimens relates to its spatial relationship with invasive cancer. This has prompted its use as a marker for concomitant cancer ('missed cancer'). In follow-up studies of men in whom there is clinical suspicion of cancer but only high-grade PIN on initial needle biopsies, the risk of finding cancer on rebiopsy is 27-100% ( Table 1 ). Most of these were retrospective analyses and therefore the detection rates may reflect clinical bias in the selection of men for rebiopsy. Cancer may be diagnosed in biopsies contralateral to the side of the original PIN in over onethird of cases, and accordingly multiple systematic biopsies are recommended23.
In contrast, the risk of cancer on rebiopsy of patients with low-grade PIN seems to be similar to that for patients without PIN and rebiopsy is not indicated on the basis of this finding alone ( Table 1 ). The diagnosis of low-grade PIN by itself does not currently provide any information that contributes to further clinical management.
Several studies suggest that the risk of subsequent cancer in men with high-grade PIN is related to serum prostatespecific antigen (PSA) levels. PIN is associated primarily with luminal abnormalities and itself probably does not Luminal cells represent a differentiated compartment, derived from basal cells, that have acquired an exocrine secretory phenotype, androgen receptors and androgen sensitivity, but their proliferative capacity is limited. They from these cells. This layer, unlike the basal cell layer, is supported by continuous androgenic stimulation36. Differentiation into luminal cells is most probably induced by the action of androgens on the androgen-responsive target cells within the basal cell layer37. Oestrogens appear to block the progression of basal cells to luminal cells, an effect that potentially increases genetic instability within the basal cell 38. layer38 Neuroendocrine cells represent a minor cell population within normal, hyperplastic and dysplastic epithelium. They are believed to represent a terminally differentiated, nonproliferative, phenotype derived from alternative differentiation of basal stem cells rather than by migration of neural crest cells39.
In normal prostatic epithelium, proliferative activity within the basal cell layer activity is controlled by various growth regulators. Androgens are recognized as necessary but not sufficient for sustained proliferation, and various growth factors, their receptors, oncogenes and tumour suppressor genes are important in the regulation of normal and malignant prostatic growth4O.
EPITHELIAL DIFFERENTIATION AND PROLIFERATION IN PIN
Prostate cancer arises from epithelium that lines the acinarduct structures. Most cancers are predominantly composed of (exocrine) secretory cells and produce PSA. Neuroendocrine differentiation is found to some degree in virtually all prostatic carcinomas but most frequently in poorly differentiated tumours and androgen-independent disease. These cells may be derived from dedifferentiation of exocrine cells in the course of malignant progression4l. Recent developments support the concept that the initial steps involved in neoplastic transformation occur within the stem cells and result in arrested differentiation36. Progression is associated with acquisition of an increasing number of genetic mutations and instability42.
The continuum between normal epithelium, PIN and cancer is paralleled by progressive abnormalities of normal growth regulation and cellular differentiation with increasing proliferative activity in the luminal cell layer and loss of markers of secretory differentiation (such as PSA). Intermediate proliferative activity in PIN has been demonstrated by various methods including AGNOR (silver staining nuclear organizer regions) and nucleolar counting, expression of proliferative markers such as Ki-67 and PCNA (proliferating cell nuclear antigen) and thymidine labelling43.
Epidermal growth factor receptor (EGFR), transforming growth factor-alpha (TGF-alpha) and c-erb in particular are involved in the regulation of growth of prostatic cell lines. Their expression in the basal and luminal cellular express cytokeratins 8 and 18, and PSA is mostly derived compartrnents shows similar characteristics in high-grade 535 PIN and cancer; in low-grade PIN their expression is near normal. In AAH, there are few changes in their expression that resemble carcinoma. Androgen receptor expression is usually higher in cancer than in benign tissue. PIN may sometimes be associated with increased androgen receptor, rather more in basal cells than in luminal cells. EGFR is strongly expressed in the basal cells of benign prostatic hyperplasia. Increased expression has been seen in the luminal cells of high-grade PIN where EGFR is upregulated in the concomitant cancer (Harper, personal communication). This receptor is not universally increased in carcinoma. TGF-alpha is expressed weakly in benign prostatic epithelium, but may be overexpressed in certain tumours, and in these cases increased expression may be demonstrated in corresponding high-grade PIN. Similarly, c-erb-B2 normally stains basal cells; there is minor staining in PIN and occasional positivity in cancer.
Growth factors that may have angiogenic potential include basic fibroblast growth factor-2 (FGF-2) and vascular endothelial growth factor (VEGF). VEGF is seen in some luminal cells and not in basal cells. Expression does not differ between benign and dysplastic epithelium. FGF-2 can be demonstrated in occasional normal luminal cells, but not in the basal cell layer. Staining is reduced in PIN and cancer.
GENETIC MUTATIONS IN PIN
A multitude of chromosomal and genetic abnormalities have been described in the progression of normal epithelium through the grades of PIN to invasive cancer, clustering at the transition from benign epithelium5 42A44,45. The techniques used include fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR) and comparative genomic hybridization (CGH) using paraffin blocks and microdissection techniques. They demonstrate the increasing variability of cell DNA content and genetic instability that characterize the course of malignant disease.
Programmed cell death, called apoptosis, plays an important role in the regulation of normal tissue growth, and its derangement following malignant transformation is of considerable interest. It may occur in response to DNA injury, providing a mechanism for the removal of genetically abnormal cells. The frequency of apoptotic bodies is greatest in invasive cancer, intermediate in high grade PIN and lowest in benign prostatic epithelium. Androgen ablation leads to an increased frequency of apoptotic bodies in benign prostatic tissue, but this effect in neoplastic epithelium is debated16 '17 Apoptosis is regulated by a variety of genes and their products. Bcl-2 and bax are two functionally antagonistic proteins that may be expressed abnormally in malignancy.
Bcl-2 is a cell death suppressor while bax is a cell death expression is confined to cytoplasm of the basal epithelial cells. The dysplastic luminal epithelium of high grade PIN shows increased bcl-2 expression compared with both benign prostatic epithelium and associated organ-confined prostate cancer50'51. It has been suggested that the prolonged lifespan of dysplastic cells which results from the aberrant expression of bcl-2 may predisposed the epithelium to genetic instability and ultimately lead to an invasive phenotype35. Bax expression has been found similar in benign prostatic tissue, PIN and associated cancer49.
The p53 tumour suppressor gene is one of the most frequently mutated genes in human cancer. Wild-type p53 plays a role in the cell response to DNA damage that results either in cellular arrest with DNA repair or apoptosis. Mutant p53 is unable to mediate this effect, but biological activity and stability of the tissue are not necessarily altered. Wild type p53 has a short half life and is not normally detected by immunohistochemistry, but when it is mutated the gene product accumulates. While immunopositivity is not always indicative of mutant protein, it has been shown to correlate with the mutation in prostate cancer. In high grade PIN, demonstration of p53 is variable and difficult to interpret. Other studies have shown that mutation is generally acquired late in the natural history of prostate cancer and is present much more frequently in metastatic than in localized disease50.
The prognostic value of genetic changes in early stage cancer and their therapeutic implications is currently the subject of intense research in order to establish a better understanding of the factors which influence the development of prostate cancer and identify those which determine its subsequent progression. Some mutations occur more commonly than others; their pattern may differ between discrete tumour foci within the same prostate; and it would appear that in multifocal disease, metastases may share genetic mutations with only a single focus of the primary disease5. This underlies the importance of adequate diagnostic sampling for planning clinical management.
ANGIOGENESIS IN PIN
Angiogenesis is essential to support the growth and progression of malignant tumours. It involves activation of endothelium, proteolytic destruction of stromal and capillary basement membrane, endothelial cell proliferation, migration of endothelial cells towards angiogenic stimuli and formation of patent capillaries. Number of vessels, microvessel density, capillary length, endothelial cell count and morphology of the vessels themselves have been examined in relation to prostate cancer. In PIN, microvessel density is intermediate between benign and malignant prostatic tissue. Markers such as PCNA indicate promoter. In the normal and hyperplastic prostate, bcl-2 that there is a progressive increase in endothelial proliferation in capillaries from normal to PIN and cancer. Similarly collagenase type 4, which may have a role in tumour invasion by causing stromal destruction and allowing endothelial cell migration, is expressed in progressively greater degrees in PIN and cancer52.
ENDOCRINE TREATMENT AND PIN
Adenocarcinoma of the prostate is sensitive to androgen deprivation in most patients, and for over 50 years endocrine manipulation has been the first-line treatment for advanced disease. Prior to radical prostatectomy, endocrine treatment may decrease surgical margin involvement but its effect on long-term recurrence rates and survival is unknown.
After endocrine treatment, there is a reduction in overall prostatic size. Luminal cells are exfoliated and glands become atrophic and dilated. In the benign prostate, basal cell hyperplasia and squamous metaplasia may be observed. Such changes are variable both within the same organ and between patients. An increase in tumour grade may also be observed52. Sometimes there may be fibrosis or clear cell change, or lymphocyte or eosinophil infiltration. The clinical and pathological implications are difficult to evaluate.
The prevalence and extent of PIN seems to decrease after endocrine treatment in patients undergoing radical prostatectomy52,53. When present, PIN is usually adjacent to the cancer and it is observed far less commonly as an isolated abnormality. This suggests that regression may occur preferentially before the development of a malignant phenotype. Reversion of morphological abnormalities cannot be taken to indicate that the molecular and genetic abnormalities associated with malignant disease are absent and that the abnormal stem cell population is eliminated. It is quite possible that some abnormal cytological features of cancer cells cannot be expressed without androgenic stimulation.
CHEMOPREVENTION OF PROSTATE CANCER AND PIN
A more desirable and possibly more cost-effective means of reducing the morbidity and mortality of prostate cancer may be through chemoprevention-that is, administration of one or more non-cytotoxic chemical compounds-in men at risk of the disease. Prostatic carcinogenesis seems to be a multistep process associated with increasing genetic heterogeneity, and thereby metastatic capability is acquired over many months or years54. The long natural history of prostate cancer imposes practical difficulties in evaluating possible chemopreventive agents in clinical trials, and interest has focused on high-grade PIN as a surrogate possibility that at least some of the early events that occur in the initiation and promotion of carcinogenesis may be inhibited or reversed by the administration of non-toxic agents is supported by the histological changes that occur with anti-androgen therapy.
The possibility that prostatic 5-alpha reductase inhibition may have chemopreventive activity is based on the observation that eunuchs, and genetic males with 5-alphareductase deficiency, do not develop prostate cancer56. This enzyme converts testosterone to the physiologically active intracellular androgen dihydrotestosterone, and finasteride selectively inhibits the prostatic (type II) isozyme. Currently, a randomized trial in the USA is evaluating the impact of finasteride versus placebo on the subsequent incidence of histologically proven prostate cancer in 18 000 men over the age of 55 years57. Other chemopreventive agents, including synthetic retinoids and polyamine synthesis inhibitors, also merit investigation58. If the natural history of PIN can be modulated by such strategies, there may be a further beneficial reduction in the subsequent incidence of invasive carcinoma. CONCLUSION PIN does not of itself warrant therapy since it is not necessarily associated with invasive disease. However, highgrade PIN does indicate a significantly increased risk of cancer, and therefore should be reported by pathologists examining needle biopsy specimens. In this context, it is important to distinguish those men with concomitant cancer that was not sampled on the initial biopsy from those without cancer who are at risk of developing malignant disease in the future. Thus, careful follow-up with rebiopsy should be recommended for all men who would be potential candidates for radical treatment. Cores should be obtained systematically from the entire gland as well as from the sites of palpable or ultrasonographic abnormality. For men without evidence of invasive cancer on rebiopsy, careful follow-up is required. The optimum timing of subsequent biopsies has not been established and current practice tends to be balanced between the urologist's concern about possible associated cancer and the patient's willingness to undergo rebiopsy: a six to twelve month interval would usually be acceptable.
For men at risk of prostate cancer who have low-grade PIN or benign findings on needle biopsy, the need for rebiopsy depends upon clinical rather than histological factors. Low-grade PIN alone is not associated with increased risk of cancer on rebiopsy; it conveys no additional clinical information regarding subsequent cancer risk and probably should not be reported routinely.
Understanding of the biological events associated with the development of PIN will provide a rational basis for the morphological marker for early prostate cancer5s. The r53 7 development of new diagnostic tools and therapeutic strategies. Future studies may identify molecular and genetic factors that distinguish men who develop clinical disease from those who do not.
